Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…Abstract Number: 0014 • ACR Convergence 2021
Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which is characterized by erosive arthritis and systemic inflammation. Tofacitinib (TFCN) is a Janus…Abstract Number: 1775 • ACR Convergence 2021
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…Abstract Number: 1848 • ACR Convergence 2021
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…Abstract Number: 0532 • ACR Convergence 2021
Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Background/Purpose: There is a pressing need of identifying patients suffering the rapid progressive phenotype of Osteoarthritis (RPOA) to implement prevention strategies and to include them…Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…Abstract Number: 0965 • ACR Convergence 2021
Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We…Abstract Number: 0648 • ACR Convergence 2020
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
Background/Purpose: Dual Energy CT Scan (DECT) can detect monosodium urate crystals in joints and periarticular tissues. EULAR gout guidelines (Richette, 2020) recognized DECT's value in…Abstract Number: 1807 • ACR Convergence 2020
The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
Background/Purpose: Lupus nephritis is common clinical manifestation and contributes significantly to mortality in systemic lupus erythematosus (SLE). Recently several studies has been reported that severity of…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 18
- Next Page »